Immunology

Items 1-10 of 42

Page
per page
Set Descending Direction
  1. 20S Immunoproteasome (human) (untagged)
    SBB-PP0144
    SBB-PP0144-C02525 µg
    CHF 507.00
    NEW 20S Immunoproteasome (human) (untagged)
  2. 20S Immunoproteasome (human) (untagged)
    SBB-PP0004
    SBB-PP0004-C02525 µg
    CHF 404.00
    20S Immunoproteasome vs. 20S Constitutive Proteasome Activity: 20S immunoproteasome is most active against Suc-LLVY-AMC (SBB-PS0010), Ac-PAL-AMC (SBB-PS0007), and Ac-ANW-AMC (SBB-PS0009) substrates, representing physiologically relevant chymotrypsi
  3. 20S Immunoproteasome (mouse) (untagged)
    SBB-PP0083
    SBB-PP0083-C02525 µg
    CHF 360.00
    20S Immunoproteasome (mouse) (untagged)
  4. 20S Immunoproteasome (rat) (untagged)
    SBB-PP0046
    SBB-PP0046-C05050 µg
    CHF 360.00
    20S Immunoproteasome (rat) (untagged)
  5. CD304 (human)-muIg Fusion Protein
    ANC-557-020.
    ANC-557-02025 µg
    CHF 551.00
  6. CD304 (human)-muIg Fusion Protein (preserviative free)
    ANC-557-820.
    ANC-557-82025 µg
    CHF 551.00
  7. CD38 (human) (rec.) (His) (active) (10µg)
    BBL-2275
    BBL-2275-C01010 µg
    CHF 782.00
    CD38 (human) (rec.) (His) (active) (10µg)
  8. Fc (LALA-PG)-KIH (human):Irisin (monomeric) (rec.)
    AG-40B-0246
    AG-40B-0246-C05050 µg
    CHF 440.00

    Replaces AG-40B-0115

    Fc (LALA-PG)-KIH (human):Irisin (monomeric) (rec.)
  9. Frizzled-5 (human):Fc (human) (rec.)
    AG-40B-0133
    AG-40B-0133-C05050 µg
    CHF 290.00
    AG-40B-0133-30503 x 50 µg
    CHF 575.00
    Figure: Frizzled-5 (human):Fc (human) (rec.) (AG-40B-0133) efficiently inhibits Wnt3a activation. Methods: Inhibition of Wnt3a activation by Frizzled-5 (human):Fc (human) (rec.) was measured by using HEK293 cells transfected with a plasmid c
  10. HA-Ubiquitin-propargylamide (human) (rec.) (HA)
    SBB-PS0124
    SBB-PS0124-C05050 µg
    CHF 366.00
    HA-Ubiquitin-propargylamide (human) (rec.) (HA)

Items 1-10 of 42

Page
per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.